The role of transdermal compounding in opioid safety

Caitlin V. Bucher, PharmD; A.J. Day, PharmD; Maria Carvalho, PhD

doi:10.5055/jom.2018.0425

Authors

Caitlin V. Bucher, PharmD
A.J. Day, PharmD
Maria Carvalho, PhD

DOI:

https://doi.org/10.5055/jom.2018.0425

Keywords:

transdermal medications, compounded medications, opioid safety, pain management

Abstract

Since the number of prescriptions for opioid medications have continued to rise, there have been questions about the safety of using opioids in pain management. Traditionally, opioid analgesics were reserved for a few select conditions, such as terminal illness and surgery, but currently opioids have been readily prescribed for multiple conditions. The objective of this manuscript is to clarify the current state of opioid use and to discuss alternative transdermal analgesic therapies in pain management. Transdermal compounded medications are patient-specific and customizable to include different types of drugs, in various dosage strengths, that are to be delivered simultaneously in one application. Due to the different origins and types of pain, treatments may be most beneficial with multiple classes of drugs with various mechanisms of action. In addition, combination drug therapy may include nontraditional pain management options, and has the ability to maximize therapeutic effects of medications through additive or synergistic properties, without increasing the dosage strengths of the drugs. Many of the challenges faced when using oral opioid therapy may be overcome by using transdermal drug delivery since this route of administration reduces adverse effects, increases patient compliance, and limits exposure to potentially abusive drugs. Although prescribing practices surrounding opioids remains to be a controversial topic, the use of compounded pain medications may help healthcare providers effectively treat their patients while avoiding the use of addictive drugs.

Author Biographies

Caitlin V. Bucher, PharmD

Xavier University of Louisiana College of Pharmacy, Louisiana, New Orleans

A.J. Day, PharmD

Director of Clinical Services, Professional Compounding Centers of America (PCCA), Houston, Texas

Maria Carvalho, PhD

Manager of PCCA Science; Professional Compounding Centers of America (PCCA), Houston, Texas

References

Meldrum ML: A capsule history of pain management. JAMA. 2003; 290(18): 2470-2475.

Nahin RL: Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015; 16(8): 769-780.

Dowell D, Haegerich TM, Chou R: CDC Guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016; 315(15): 1624-1645.

Prince V: Pain management in patients with substance-use disorders. PSAP (Pharmacotherapy Self-assessment Program)-VII, Book 5: Chronic Illnesses 7th edn. 2011. ACCP (American College of Clinical Pharmacy).

Cheatle MD O'Brien CP: Opioid therapy in patients with chronic noncancer pain: Diagnostic and clinical challenges. Adv Psychosom Med. 2011; 30: 61-91.

Physicians for Responsible Opioid Prescribing. Cautious, evidence-based opioid prescribing. [Online] 2016. Available at http://www.supportprop.org/wp-content/uploads/2014/01/PROP_OpioidPrescribing.pdf. Accessed August 3, 2017.

Juurlink DN, Dhalla IA: Dependence and addiction during chronic opioid therapy. J Med Toxicol. 2012; 8(4): 393-399.

Centers for Disease Control and Prevention (CDC). Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR. 2016; 64(50): 1378-1382.

Center for Behavioral Health Statistics and Quality. 2014 National Survey on Drug Use and Health: Methodological summary and definitions, 2015. Rockville, MD: Substance Abuse and Mental Health Services Administration.

Boscarino JA, Hoffman SN, Han JJ: Opioid-use disorder among patients on long-term opioid therapy: Impact of final DSM-5 diagnostic criteria on prevalence and correlates. Subst Abuse Rehabil. 2015; 6: 83-91.

Vowles KE, McEntee ML, Julnes PS, et al.: Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis. Pain. 2015; 156(4): 569-576.

Jamison RN, Sheehan KA, Scanlan E, et al.: Beliefs and attitudes about opioid prescribing and chronic pain management: Survey of primary care providers. J Opioid Manag. 2014; 10(6): 375-382.

Benyamin R, Trescot AM, Datta S, et al.: Opioid complications and side effects. Pain Phys. 2008; 11(suppl 2): S105-S120.

Branvold A, Carvalho M: Pain management therapy: The benefits of compounded transdermal pain medication. J Gen Pract. 2014; 2: 188.

Zagaria MAE: Chronic opioid therapy for noncancer pain. US Pharm 2010; 35(5): 20-26.

Mainar AS, Artieda RN, Morillo JV, et al.: Treatment profiles and costs of patients with chronic pain in the population setting. Clinicoecon Outcomes Res. 2012; 4: 39-47.

Birnbaum HG, White AG, Schiller M, et al.: Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011; 12(4): 657-667.

Scheindlin S: Transdermal drug delivery: Past, present, future. Mol Interv. 2004; 4(6): 308-312.

Jorge LL, Feres CC, Teles VEP: Topical preparations for pain relief: Efficacy and patient adherence. J Pain Res. 2011; 4: 11-24.

Hochberg MC, Altman RD, April KT, et al.: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012; 64(4): 465-474.

Stanos SP: Topical agents for the management of musculoskeletal pain. J Pain Symptom Manag. 2007; 33(3): 342-355.

Derry S, Wiffen P, Moore A: Topical nonsteroidal anti-inflammatory drugs for acute musculoskeletal pain. JAMA. 2016; 315(8): 813-814.

Baer PA, Thomas LM, Shainhouse Z: Treatment of osteoarthritis of the knee with a topical diclofenac solution: A randomized controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord. 2005; 6: 44.

Bookman AA, Williams KS, Shainhouse JZ: Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: A randomized controlled trial. CMAJ. 2004; 171(4): 333-338.

Tam E, Furlan AD: Transdermal lidocaine and ketamine for neuropathic pain: A study of effectiveness and tolerability. Open Neurol J. 2012; 6: 58-64.

ACPM (American College of Preventive Medicine). Medication adherence: Improving health outcomes time tool 2011. Available at http://www.acpm.org/?MedAdhereTTProviders. Accessed August 17, 2017.

Paudel KS, Milewski M, Swadley CL, et al.: Challenges and opportunities in dermal/transdermal delivery. Ther Deliv. 2010; 1(1): 109-131.

Peppin JF, Albrecht PJ, Argoff C, et al.: Skin matters: A review of topical treatments for chronic pain. Part one: Skin physiology and delivery systems. Pain Ther. 2015; 4(1): 17-32.

Safaeian P, Mattie R, Hahn M, et al.: Novel treatment of radicular pain with a multi-mechanistic combination topical agent: a case series and literature review. Anesth Pain Med. 2016; 6(2): e33322.

Risser A, Donovan D, Heintzman J, et al.: NSAID prescribing precautions. Am Fam Phys. 2009; 80(12): 1371-1378.

Reis De Carvalho MJ: Extemporaneously Compounded Oral Medicines in European Hospital Pharmacies. Doctoral Thesis. 2013, UCL (University College London).

Dworkin RH, O'Connor AB, Audette J, et al.: (2010). Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc. 2010; 85(suppl 3): S3-S14.

Mao J, Gold MS, Backonja MM: Combination drug therapy for chronic pain: A call for more clinical studies. J Pain. 2011; 12(2): 157-166.

Allen LV: Ketamine hydrochloride 5%, gabapentin 10%, clonidine hydrochloride 0.2%, and baclofen 2% in Lipoderm. Int J Pharm Compnd. 2016; 20(3): 231.

Somberg JC, Molnar J: Retrospective evaluation on the analgesic activities of 2 compounded topical creams and Voltaren Gel in chronic noncancer pain. Am J Ther. 2015; 22(5): 342-349.

Warner M, Tuder D: A brief survey on prescriber beliefs regarding compounded topical pain medications. Int J Pharm Compnd. 2014; 18(3): 182-188.

Deyo RA, Smith DH, Johnson ES, et al.: Opioids for back pain patients: Primary care prescribing patterns and use of services. J Am Board Fam Med. 2011; 24(6): 717-727.

Argoff CE, Galer BS, Jensen MP et al.: Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: Assessment with the Neuropathic Pain Scale. Curr Med Res Opin. 2004; 20(suppl 2): S21-S28.

Wolfgang K, Helmut F, Ulrike K, et al.: Capsicum pain plaster in chronic non-specific low back pain. Arzneimittelforschung. 2001; 51(11): 896-903.

SAMHSA (Substance Abuse and Mental Health Services Administration). Managing chronic pain in adults with or in recovery from substance use disorders. TIP (Treatment Improvement Protocol) Series 2012, 54, Report No: (SMA) 12-4671, Rockville (MD).

Christiansen J, White L: Unique challenges in compounding: Managing severe musculoskeletal pain in a recovered substance abuser. Int J Pharm Compnd. 2010; 14(4): 310-314.

Bassani AS, Banov D, Phan H: Characterization of the percutaneous absorption of ketoprofen using the Franz skin finite dose model. Postgrad Med. 2016; 128(2): 262-267.

Bassani AS, Banov D, Phan H: In vitro characterization of the percutaneous absorption of lorazepam into human cadaver torso skin, using the Franz skin finite dose models. J Pharm Drug Deliv Res. 2015a; 4(2). Available at http://dx.doi.org/10.4172/2325-9604.1000131.

Bassani AS, Banov D, Simmons C, et al.: In vitro characterization of the percutaneous absorption of tramadol into inner ear domestic feline skin using the Franz skin finite dose model. Vet Med Anim Sci. 2015b, 3(3). doi: 10.7243/2054-3425-3-3.

Bassani AS, Banov D: Evaluation of the percutaneous absorption of ketamine HCl, gabapentin, clonidine HCl, and baclofen, in compounded transdermal pain formulations, using the Franz finite dose model. Pain Med. 2016; 17(2): 230-238.